Aug 08, 2022 8:30am EDT Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022
Jun 13, 2022 8:00am EDT Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review
May 16, 2022 5:00pm EDT Inhibikase Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
May 10, 2022 8:05am EDT Inhibikase Therapeutics to Participate at the H.C. Wainwright Global Investment Conference
May 09, 2022 4:05pm EDT Inhibikase Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
Apr 21, 2022 4:05pm EDT Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
Mar 31, 2022 5:00pm EDT Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity
Mar 28, 2022 8:00am EDT Inhibikase Therapeutics to Participate in the Next Generation Kinase Inhibitors Summit
Mar 25, 2022 8:00am EDT Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022